U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505043) titled 'First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics' on March 11.
Brief Summary: ISH0688 is a human IgG1 Fc-FGF21 fusion protein. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of ISH0688 via subcutaneous injection.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Healthy Subjects
Hyperlipidemia, Hypertriglyceridemia
Intervention:
DRUG: ISH0688 for injection
75、150、300、600 mg; s.c. Q4W; Sterile powder for inje...